631 related articles for article (PubMed ID: 33102749)
21. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
Arshad T; Golabi P; Henry L; Younossi ZM
Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
Berkan-Kawińska A; Piekarska A
Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
[No Abstract] [Full Text] [Related]
24. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Said A; Ghufran A
World J Clin Oncol; 2017 Dec; 8(6):429-436. PubMed ID: 29291167
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
[TBL] [Abstract][Full Text] [Related]
26. Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature.
Singh S; Kuftinec GN; Sarkar S
J Clin Transl Hepatol; 2017 Mar; 5(1):76-81. PubMed ID: 28507930
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
28. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
[TBL] [Abstract][Full Text] [Related]
29. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
31. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
32. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
33. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
34. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
35. The fecal mycobiome in non-alcoholic fatty liver disease.
Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study.
Gkolfakis P; Tziatzios G; Leite G; Papanikolaou IS; Xirouchakis E; Panayiotides IG; Karageorgos A; Millan MJ; Mathur R; Weitsman S; Dimitriadis GD; Giamarellos-Bourboulis EJ; Pimentel M; Triantafyllou K
Microorganisms; 2023 Mar; 11(3):. PubMed ID: 36985296
[TBL] [Abstract][Full Text] [Related]
39. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
40. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
